Hi [[ session.user.profile.firstName ]]

Roche CDx Insights

  • Date
  • Rating
  • Views
  • PD-L1 Assays – More than just an antibody
    PD-L1 Assays – More than just an antibody
    Dr. Michael Flores Recorded: Sep 18 2018 33 mins
    In this webinar, Dr. Flores will summarize the PD-L1 testing assays currently available on market and address the importance of understanding the different scoring algorithms developed for their respective PD-1/PD-L1 immunotherapies. You will learn about a system approach to testing and where to find further information on how to appropriately interpret the specific PD-L1 assay you are working with.
  • Multiplexed immunofluorescence and digital image analysis for clinical use
    Multiplexed immunofluorescence and digital image analysis for clinical use
    Mehrnoush Khojasteh, PhD & Lei Tang, PhD Recorded: Jun 28 2018 63 mins
    There is an ever increasing need to understand the role of the Tumor Microenvironment (TME) in Cancer Immunotherapy. In this webinar, Drs. Lei Tang, PhD and Mehrnoush Khojasteh,PhD of Roche Tissue Diagnostics (Ventana Medical Systems, Inc.), present their work on multiplex immunofluorescence staining and digital pathology analysis in a CAP/CLIA certified laboratory. Multiplexed immunohistochemistry (IHC) enables the spatial characterization of TME immune cells and tumor cells by detecting multiple biomarkers while preserving tissue morphology. Co-expression of multiple biomarkers and relative spatial relationships requires whole slide digital pathology image analysis algorithms that are tailored to individual assays and their intended uses. The process described in this presentation demonstrates how multiplexing and digital pathology enable biotech and pharmaceutical research and development teams to explore the potential medical value of specific biomarkers,
  • Immunotherapy biomarkers: friends or foes?
    Immunotherapy biomarkers: friends or foes?
    Professor Keith Kerr, MB, ChB, FRCPath, FRCPE, Consultant Pathologist, Department of Pathology, University of Aberdeen, Aberd Recorded: Jun 28 2017 60 mins
    Immunotherapy is changing the cancer care paradigm: for a small but significant group of patients, cancer has become a chronic disease and immunotherapy biomarkers like PD-L1 play an important role. In this presentation, Professor Kerr will provide a summary of the immunotherapy treatment landscape, address what makes immunotherapy biomarkers unique compared to biomarkers like HER-2 and ALK, describe the function (physiologic and as a biomarker) of PD-L1 and other biomarkers relevant to the PD-1/PD-L1 pathway. He will also address the role of emerging immunotherapy biomarkers that are independent of the PD-1/PD-L1 pathway.
  • From biopsy to treatment: A tissue journey through pathology
    From biopsy to treatment: A tissue journey through pathology
    Zin Htway, PhD, MBAHM, CT (ASCP, IAC), Maria Magana, Danielle Westfall, MD, Los Robles Hospital and Medical Center Recorded: May 12 2017 43 mins
    Surgical procurement of adequate tissue can be challenging. This presentation will be an in-depth look at rapid on-site evaluation of tissue biopsies from various sites. Best practices for handling, grossing and histology sectioning of tissue biopsies for companion diagnostics will be discussed. This will be followed by a brief overview of this approach applied to immunohistochemistry stains and fluorescence in situ hybridization.
  • Large B-Cell Lymphomas: WHO 2016 Classification Update and Predictive Biomarkers
    Large B-Cell Lymphomas: WHO 2016 Classification Update and Predictive Biomarkers
    Yaso Natkunam, MD, PhD, Professor of Pathology, Director of Hematopathology, Stanford University School of Medicine Recorded: Mar 29 2017 58 mins
    Join us for the March CDx Insights webinar “Large B-Cell Lymphomas: WHO 2016 Classification Update and Predictive Biomarkers.” Our speaker is Yaso Natkunam, MD, PhD, Professor of Pathology and Director of Hematopathology at Stanford University School of Medicine. Dr Natkunam will review key updates to the classifications of large B-cell lymphomas in the “2016 revision of the World Health Organization classification of lymphoid neoplasms.” She will also discuss the role of diagnostic and predictive biomarkers in DLBCL, high grade B-cell lymphoma and other large B-cell lymphomas.
  • Part 2: Tumor heterogeneity and immuno-oncology
    Part 2: Tumor heterogeneity and immuno-oncology
    Tom Grogan, MD, Founder, Senior Vice President, Ventana Medical Systems Inc. Recorded: Mar 15 2017 2 mins
    View two new CDx Insights videos “Part 1: CDx, IHC and tumor heterogeneity” and “Part 2: Tumor heterogeneity and immuno-oncology” with Tom Grogan, MD, Founder and Senior Vice President of Scientific Affairs of Ventana Medical Systems, Inc. Dr. Grogan addresses the role of IHC in companion diagnostics, assessment of heterogeneity and the interplay between the immune system and cancer.
  • Part 1: CDx, IHC and tumor heterogeneity
    Part 1: CDx, IHC and tumor heterogeneity
    Tom Grogan, MD,Senior Vice President, Founder, Ventana Medical Systems Inc. Recorded: Mar 15 2017 4 mins
    View two new CDx Insights videos “Part 1: CDx, IHC and tumor heterogeneity” and “Part 2: Tumor heterogeneity and immuno-oncology” with Tom Grogan, MD, Founder and Senior Vice President of Scientific Affairs of Ventana Medical Systems, Inc. Dr. Grogan addresses the role of IHC in companion diagnostics, assessment of heterogeneity and the interplay between the immune system and cancer.
  • Predictive assays: Analytic validation, clinical validation and clinical utility
    Predictive assays: Analytic validation, clinical validation and clinical utility
    Krista Acosta, Nicole Schechter, PSM, PMP, Al Yates, PhD Recorded: Aug 25 2016 55 mins
    Predictive assays are a key element of personalized healthcare because these assays aid physicians in selecting individuals who are most likely or least likely to benefit from specific therapies. In addition to analytical validation, predictive assays require clinical validation to establish their clinical utility. Krista Acosta, Manager, CDx Pharma Services Assay Development, Nicole Schechter, PSM, PMP, CDx Director, Project Leader and Alton Yates PhD, Senior Manager, Clinical Sciences Management, will address the development and performance differences between predictive assays developed under in vitro diagnostic regulations and laboratory developed tests.
  • The dangers of using a laboratory developed test as a companion diagnostic
    The dangers of using a laboratory developed test as a companion diagnostic
    Keith Miller, FIBMS, Director, UKNEQAS-ICC&ISH Recorded: Jun 1 2016 51 mins
    Companion diagnostic tests are most commonly used to determine patient eligibility for specific therapies and are designed to ensure the therapy is administered safely to patients who are most likely to benefit. Thus, companion diagnostic tests are crucial in facilitating personalized healthcare for the individual patient. Join us as Keith Miller, FIBMS, Director of the United Kingdom National External Quality Assessment Scheme for Immunohistochemistry and In Situ Hybridisation (UKNEQAS-ICC&ISH), addresses the inherent risks in using laboratory developed tests as companion diagnostics, and the role of external quality assessment schemes (EQA) in helping laboratories monitor and maintain quality testing.
  • Personalized Healthcare in Oncology:  Past, Present and Future
    Personalized Healthcare in Oncology: Past, Present and Future
    Eric Walk MD, FCAP, Chief Medical Officer, Ventana Medical Systems, Inc. Recorded: Feb 25 2016 60 mins
    Personalized healthcare continues to evolve. There are now five pillars of cancer therapy and two of the five, targeted therapies and immunotherapy, are personalized approaches. Join us at 9 AM MST, February 25, 2016 as Eric Walk MD, FCAP, Chief Medical Officer, Ventana Medical Systems, Inc. (Ventana), addresses how personalized healthcare has evolved and impacted cancer diagnosis and therapy.

Embed in website or blog